The value of c-kit in the diagnosis of biphenotypic acute leukemia TO 
THE EDITOR
The European Group for the immunological classification of leukemias (EGIL) reported guidelines for the characterization and diagnosis of the various subgroups of acute leukemias on the basis of the expression of lymphoid and myeloid lineage associated markers. 1 One of the aims of the group was to assess the validity and specificity of the detection of some differentiation antigens, which although not widely used, could be potentially useful for lineage assignment. Among others, there was CD117 or c-kit, a monoclonal antibody (McAb) that identifies the receptor for the stem-cell growth factor and which plays an important functional role in hemopoiesis. There were contradictory views with regard to the myeloid specificity of c-kit. Some studies, albeit based on small series of patients, documented a variable proportion of acute lymphoblastic leukemia (ALL) cases to be c-kit+ (for review see Ref.
2). For this reason, in the scoring system to define biphenotypic acute leukemia, c-kit provisionally was given a score of 0.5 point until its probable still uncertain myeloid specificity was demonstrated by testing a large number of ALL samples. 1 We can now establish and confirm the specificity of CD117 (c-kit) for the myeloid lineage supported by our study on close to 2000 acute leukemia cases which included 819 pediatric and adult ALL. 3 Blast cells from only a minority (4%) of ALL expressed c-kit, and most of these cases were very early T-ALL (T-1) and/or had other myeloid features, eg CD13 and/or CD33 expression. Therefore, when considering the scoring system to define biphenotypic acute leukemias, the EGIL proposes to assign to c-kit a score of 1 point for the myeloid lineage as it has been shown to be more specific than CD13 and CD33 which have scores of 1 ( Table 1) . 
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